Since April 2020, the ACT-Accelerator partnership has supported the fastest, most coordinated, and successful global effort in history to develop tools to fight a disease. The ACT-Accelerator has driven real progress, delivering diagnostic tests, personal protective equipment (PPE), treatments including medical oxygen, and vaccines.
But inequitable access to these COVID-19 tools is severely hindering the pandemic response in low- and middle-income countries and new variants of concern continue to emerge around the globe. There is still much more to be done to fight this virus. Only united and through a comprehensive approach of all these interventions and tools can we defeat COVID-19.
The ACT-Accelerator will need US$23.4 billion for the period of October 2021 to September 2022 to address crucial gaps in access to COVID-19 tools and to achieve the following targets:
- Contribute towards reaching the global target of 70% vaccination coverage in all countries by mid-2022.
- Reach a minimum testing rate of at least 1 test per 1000 people per day in the 144 countries in the Diagnostics Consortium.
- Ensure 120 million COVID-19 patients in low- and middle-income countries have access to existing and emerging treatments, including medical oxygen.
- Keep 2.7 million health workers in low- and middle-income countries safe with personal protective equipment (PPE).